Searchable abstracts of presentations at key conferences in endocrinology

ea0063p621 | Diabetes, Obesity and Metabolism 2 | ECE2019

Nonclinical development of livoletide (AZP-531), a peptide analog of unacylated ghrelin for the treatment of hyperphagia in Prader-Willi syndrome

Milano Stephane , Allas Soraya , Cade Didier , Briffaux Jean-Paul , Spencer Andrew

Prader-Willi syndrome (PWS) is a rare complex endocrine disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There are no approved treatments for hyperphagia in PWS. Patients with PWS have increased circulating levels of the orexigenic hormone acylated ghrelin (AG) with a relative deficit of unacylated ghrelin (UAG). These abnormalities in AG and ...